Cockcroft D W, MacCormack D W, Newhouse M T, Hargreave F E
Can Med Assoc J. 1976 Sep 18;115(6):523-6.
Treatment with beclomethasone dipropionate aerosol (BDA), 50 mug four times daily in each nostril, was compared with placebo therapy in a double-blind non-crossover trial of 30 matched patients with allergic rhinitis induced by ragweed pollen. The trial was started at the beginning of the ragweed season and continued for 42 days. Response to treatment was assessed from information on daily diary cards, weekly objective measurements of nasal patency and measurement of total eosinophil count (TEC) before treatment and at week 4. Patients in the BDA group had significantly less (P less than 0.05) sneezing, rhinorrhea and nasal stuffiness at 36 days, cough at 10 days and antihistamine consumption at 17 days. There was no significant difference between the groups in eye symptoms, nasal airway inspiratory resistance, maximum inspiratory nasal flow or TEC. Overall comparison with previous pollen seasons by the patients indicated moderate to great improvement in 86% of the BDA group and in 13% of the placebo group (P less than 0.01). Minor side effects were noted by two patients in each group.
在一项双盲非交叉试验中，将30例匹配的豚草花粉诱发的变应性鼻炎患者分为两组，一组每日4次、每次每个鼻孔使用50μg丙酸倍氯米松气雾剂（BDA）进行治疗，另一组接受安慰剂治疗。试验在豚草季节开始时启动，持续42天。根据每日日记卡记录的信息、每周鼻腔通畅度的客观测量以及治疗前和第4周时的总嗜酸性粒细胞计数（TEC）测量结果来评估治疗反应。BDA组患者在第36天时打喷嚏、鼻溢和鼻塞症状明显减轻（P<0.05），第10天时咳嗽症状减轻，第17天时抗组胺药使用量减少。两组在眼部症状、鼻气道吸气阻力、最大吸气鼻流量或TEC方面无显著差异。患者对与之前花粉季节的总体比较表明，BDA组86%的患者有中度至显著改善，安慰剂组为13%（P<0.01）。每组各有两名患者出现轻微副作用。
